Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01969344 · ClinicalTrials.gov registry record
Study of COPD Subgroups and Biomarkers
A clinical trial of Chronic Obstructive Pulmonary Disease and COPD, sponsored by University of North Carolina, Chapel Hill.
- Active
- Registry status
- 2,981
- Enrollment target
- 14
- Study locations
NCT01969344 is a study of Chronic Obstructive Pulmonary Disease and COPD that is active but no longer recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 2,981 participants, above the 1,719-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (73% higher). The trial reports 14 study locations across 12 states.
The verdict
NCT01969344, a study of Chronic Obstructive Pulmonary Disease and COPD, is active but no longer recruiting, sponsored by University of North Carolina, Chapel Hill.
- ACTIVE NOT RECRUITING
- Registry status
- 2,981 participants
- Enrollment target
- 14
- Study locations
Study Summary
SPIROMICS I, SPIROMICS II, and SPIROMICS III are longitudinal observational studies of Chronic Obstructive Pulmonary Disease (COPD) cohort. SPIROMICS I had two primary aims: (1) To find groups of patients with COPD who share certain characteristics; (2) To find new ways of measuring whether or not COPD is getting worse and to provide new ways of testing whether a new treatment is working. SPIROMICS II had three primary aims: (1) To define the natural history of "smokers with symptoms despite preserved spirometry" and characterize the airway mucus abnormalities underlying this condition; (2) To determine the radiographic precursor lesion(s) for emphysema and identify the molecular phenotypes underlying airway disease and emphysema; (3) To advance understanding of the biology of COPD exacerbations through analysis of predisposing baseline phenotypes, exacerbation triggers and host inflammatory response. SPIROMICS III has three primary aims: (1) To identify the main forms of smoking-related airway disease that are caused by pathological airway mucus, their biological underpinnings, and their physiological significance; (2) To identify longitudinal trajectories in established and novel CT measures of emphysema, test how they predict COPD progression, and define their underlying biology; (3) To identify environmental and social determinants of health that impact disease severity and progression and their influence on lung structure, biology, and health disparities in COPD.
Conditions Studied
Study Locations (14)
California
- University of California at Los Angeles - Los Angeles
- University of California at San Francisco - San Francisco
New York
- Weill Cornell Medicine - New York
- Columbia University - New York
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Scottsdale
Colorado
- National Jewish Health - Denver
Illinois
- University of Illinois at Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,981 participants |
| Start Date | 2010-11 |
| Est. Completion | 2031-06-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01969344
The ClinicalTrials.gov registry entry for NCT01969344 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,981 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,719-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (73% higher). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01969344 reports 14 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT01969344 about?
NCT01969344 is a clinical study titled "Study of COPD Subgroups and Biomarkers". SPIROMICS I, SPIROMICS II, and SPIROMICS III are longitudinal observational studies of Chronic Obstructive Pulmonary Disease (COPD) cohort. SPIROMICS I had two primary aims: (1) To find groups of patients with COPD who share certain characteristics; (2) To find new ways of measuring whether or not ...
What is the current status of trial NCT01969344?
This trial is currently active not recruiting. The enrollment target is 2,981 participants. The study started on 2010-11. Estimated completion is 2031-06-17.
What conditions does trial NCT01969344 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis.
Who is sponsoring clinical trial NCT01969344?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01969344 being conducted?
This trial has 14 study locations across Alabama, Arizona, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study
RECRUITING
-
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
RECRUITING · NA
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
COPD Care Pathway Among Patients With Cancer
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.